Wuxi Novohope Biotechnology Co., Ltd.was established in September 2025, focusing on pet food and nutrition solutions. Its core team is led by talents with experience in listed companies and in the field of biomedicine, while the technical team comes from the Wahsheer Biotechnology Laboratory at the Chinese University of Hong Kong (where Nobel Prize winners are located). The company is the first global enterprise brand to release pet oral dissolving membrane health products.The brand mainly offers oral melt film (flash-release film) formulations. This technology utilizes the absorption of the oral mucosa. Once the product comes into contact with saliva, it melts within 10 seconds, allowing the active ingredients to directly enter the circulatory system. It is claimed that the absorption rate is as high as 95%.International debut: In May 2026, 6 products were showcased at the International Pet Exhibition in Nuremberg, Germany. The world's first pet oral coating was launched. Over 700 global customers were received and more than 100 potential clients were reached. Expansion of R&D: In June 2026, a new R&D and marketing center was opened in Shekou, Shenzhen. Compliance Certification: In July 2026, all products completed FDA food registration and obtained GS1 international product codes. They also passed professional certifications such as SDS and COA, and established a global compliance and quality control system. Acquired honors: The company has been selected for the "Feifeng Talent Program" - the Leading Technological Talent Project in 2025, and has also been shortlisted for the 2026 Wuxi Taihu Cup International Innovation Competition. The core technology of NOVOHOPE lies in its oral meltable formulation, which represents a revolutionary approach to drug delivery. Technical principle: The oral melting film is a film the size of a postage stamp. When in contact with pet saliva, it melts rapidly within 10 seconds. Its active ingredients are directly absorbed through the oral mucosa and enter the bloodstream, bypassing the digestive process that traditional oral medications must undergo in the stomach and intestines. Core advantages: High absorption rate: Claims an absorption rate of up to 95%, far exceeding the absorption level of traditional products which is approximately 35%. Overcomes physiological barriers: Perfectly adapted to the physiological characteristics of pet short intestines (less than 1.2 meters) and high stomach acid (pH value 1-3), avoiding the degradation of active ingredients in the stomach and intestines. Solving the feeding problem: The new formulation is highly palatable and can effectively address the stress issues caused by pets' refusal to eat or forced feeding.